Literature DB >> 14870962

Ziprasidone in Huntington's disease: the first case reports.

Raphael M Bonelli1, Brigitte M Mayr, Gerald Niederwieser, Franz Reisecker, Hans-Peter Kapfhammer.   

Abstract

Huntington's disease (HD) is a relentlessly progressive neuropsychiatric disorder with an underlying autosomal dominantly inherited genetic defect. Classical antipsychotics (i.e. phenothiazines or butyrophenones) are the most used medication to reduce the (probably dopamine-born) choreiform hyperkinesias. Ziprasidone is the latest of a new class of atypical antipsychotics; it has not been studied so far in this indication. We report three genetically confirmed HD patients who improved significantly in several categories of the motor scale of the Unified HD Rating Scale.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14870962     DOI： 10.1177/0269881103174009

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN： 0269-8811            Impact factor:   4.153


  10 in total

1.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Drug repositioning by integrating target information through a heterogeneous network model.

Authors:  Wenhui Wang; Sen Yang; Xiang Zhang; Jing Li
Journal:  Bioinformatics       Date:  2014-06-27       Impact factor: 6.937

3.  Patterns of serotonergic antidepressant usage in prodromal Huntington disease.

Authors:  Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Chiachi Wang; James Mills; Leigh J Beglinger; Megan M Smith; Eric A Epping; Jess G Fiedorowicz; Kevin Duff; Adam Ruggle; David J Moser
Journal:  Psychiatry Res       Date:  2012-03-05       Impact factor: 3.222

Review 4.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 5.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

6.  A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Authors:  Xin Du; Terence Y C Pang; Anthony J Hannan
Journal:  Front Neurol       Date:  2013-07-09       Impact factor: 4.003

Review 7.  Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease.

Authors:  Wooseok Im; Manho Kim
Journal:  J Mov Disord       Date:  2014-04-30

8.  Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data integration.

Authors:  Guangsheng Wu; Juan Liu; Caihua Wang
Journal:  BMC Med Genomics       Date:  2017-12-28       Impact factor: 3.063

9.  Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease.

Authors:  Lulin Huang; Li Fang; Qian Liu; Abolfazl Doostparast Torshizi; Kai Wang
Journal:  Genes Dis       Date:  2021-06-09

10.  Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.

Authors:  Jane Y Chen; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  Front Neurosci       Date:  2013-07-04       Impact factor: 4.677
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.